Main Industry
Health Care
Main Product/Service
Products and services
Allogeneic Adipose Stem Cell Bank
Allogeneic Adipose Stem Cell Bank
UnicoCell's cell bank is the leading allogeneic cell bank of adipose stem cell source in Taiwan, built in accordance with ICH regulations (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). The stem cell product, ELIXCYTER, cultured by the allogeneic cell bank has passed human clinical trials for knee osteoarthritis and chronic kidney disease.
UnicoCell's allogeneic stem cell bank is the best choice for cell starting material to be used for various indications in research units.
Autologous Stem Cell Therapy
Autologous Stem Cell Therapy
UnicoCell has been focusing on the development and application of new stem cell drugs for more than 10 years. Our cell production plant has been approved by TFDA under GTP guidance for Human Tissue Banks and human clinical trials, verified as a CPU (Cell Processing Unit) under RASMET (“The Regulation Governing the Application of Specific Medical Examination Technique and Medical Device”), and obtained the Accreditation Certificate of Foreign Cell Processor from Japan MHLW (Ministry of Health, Labor and Welfare).
With the same high standard of quality systems required by clinical trials, UnicoCell has partnered with major hospitals in Taiwan on autologous stem cell therapy for knee osteoarthritis.
Conditioned Medium
Conditioned Medium
UnicoCell has been focused on the development of stem cell related applications and technologies for the past decade.
During our study of cell culture method, we have developed a unique production method which can significantly increase the unit concentration of stem cell secretome compared to the traditional culture method. We have obtained an invention patent for our proprietary process of producing stem cell secretome.
Mass Production and CDMO
Mass Production and CDMO
The mass production process of stem cells developed by UnicoCell can increase the yield of a single batch compared to the traditional culture method. By increasing the yield, the production cost is significantly reduced with the price of cellular products more affordable for the regenerative medical needs and disease treatment.
Cryogenic Vial (Class 2 Medical Device)
Cryogenic Vial (Class 2 Medical Device)
UnicoVialR, a patented cryogenic vial, obtained approval of TFDA Class 2 medical device, received Acknowledgment letter of DMF (Drug Master File) from US FDA and won the 19th National Innovation Award.
UnicoVialR is ideal for storage of cell products and biological samples under ultra-low temperature, with a stopper invention specifically designed for clinical use.
Allogeneic Adipose Stem Cell Bank
Allogeneic Adipose Stem Cell Bank
UnicoCell's cell bank is the leading allogeneic cell bank of adipose stem cell source in Taiwan, built in accordance with ICH regulations (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). The stem cell product, ELIXCYTER, cultured by the allogeneic cell bank has passed human clinical trials for knee osteoarthritis and chronic kidney disease.
UnicoCell's allogeneic stem cell bank is the best choice for cell starting material to be used for various indications in research units.
Autologous Stem Cell Therapy
Autologous Stem Cell Therapy
UnicoCell has been focusing on the development and application of new stem cell drugs for more than 10 years. Our cell production plant has been approved by TFDA under GTP guidance for Human Tissue Banks and human clinical trials, verified as a CPU (Cell Processing Unit) under RASMET (“The Regulation Governing the Application of Specific Medical Examination Technique and Medical Device”), and obtained the Accreditation Certificate of Foreign Cell Processor from Japan MHLW (Ministry of Health, Labor and Welfare).
With the same high standard of quality systems required by clinical trials, UnicoCell has partnered with major hospitals in Taiwan on autologous stem cell therapy for knee osteoarthritis.
Conditioned Medium
Conditioned Medium
UnicoCell has been focused on the development of stem cell related applications and technologies for the past decade.
During our study of cell culture method, we have developed a unique production method which can significantly increase the unit concentration of stem cell secretome compared to the traditional culture method. We have obtained an invention patent for our proprietary process of producing stem cell secretome.
Mass Production and CDMO
Mass Production and CDMO
The mass production process of stem cells developed by UnicoCell can increase the yield of a single batch compared to the traditional culture method. By increasing the yield, the production cost is significantly reduced with the price of cellular products more affordable for the regenerative medical needs and disease treatment.
Cryogenic Vial (Class 2 Medical Device)
Cryogenic Vial (Class 2 Medical Device)
UnicoVialR, a patented cryogenic vial, obtained approval of TFDA Class 2 medical device, received Acknowledgment letter of DMF (Drug Master File) from US FDA and won the 19th National Innovation Award.
UnicoVialR is ideal for storage of cell products and biological samples under ultra-low temperature, with a stopper invention specifically designed for clinical use.
Founded Year
2022
Unified Business No.
90250984
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,920,000 (NT$)
Location of Company
Taiwan
, Tainan City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
UnicoCell's business is centered on regenerative medicine. We focus on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life.
UnicoCell's cell bank is the leading allogeneic cell bank of adipose stem cell source in Taiwan, built in accordance with ICH regulations (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). Our Gold Award new stem cell investigational product ELIXCYTER has been tested on clinical trials for knee osteoarthritis and chronic kidney disease. Stem cell derived technology is also used in the development of retinal degenerative diseases treatment and other regenerative medicine applications. We hope to contribute to society through stem cell technology research and development by continuing to improve quality and developing mass production technologies.
UnicoCell's cell bank is the leading allogeneic cell bank of adipose stem cell source in Taiwan, built in accordance with ICH regulations (The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use). Our Gold Award new stem cell investigational product ELIXCYTER has been tested on clinical trials for knee osteoarthritis and chronic kidney disease. Stem cell derived technology is also used in the development of retinal degenerative diseases treatment and other regenerative medicine applications. We hope to contribute to society through stem cell technology research and development by continuing to improve quality and developing mass production technologies.
